000119312515088183txt 20150312 000119312515088183hdrsgml 20150312 20150312062100 accession number 000119312515088183 conformed submission type sc 14d9a public document count 2 filed date 20150312 date change 20150312 subject company company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a sec act 1934 act sec file number 00553269 film number 15694366 business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 filed by company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 sc 14d9a 1 d884196dsc14d9ahtm sc 14d9a sc 14d9a united state security exchange commission washington dc 20549 schedule 14d9 amendment no 2 solicitationrecommendation statement section 14d4 security exchange act 1934 salix pharmaceutical ltd name subject company salix pharmaceutical ltd name person filing statement common stock par value 0001 per share title class security 795435106 cusip number class security william bertrand jr acting chief operating officer executive vice president general counsel salix pharmaceutical ltd 8510 colonnade center drive raleigh north carolina 27615 919 8621000 copy to christopher t cox gregory p patti jr cadwalader wickersham taft llp one world financial center new york ny 10281 212 5046000 name address telephone number person authorized receive notice communication behalf person filing statement ¨ check box filing relates solely preliminary communication made commencement tender offer purpose amendment amendment no 2 this “amendment” amends supplement solicitationrecommendation statement schedule 14d9 salix pharmaceutical ltd the “company” “we” filed security exchange commission the “sec” march 6 2015 a heretofore amended supplemented time time “schedule 14d9” schedule 14d9 relates tender offer sun merger sub inc delaware corporation “purchaser” wholly owned subsidiary valeant pharmaceutical international delaware corporation “vpi” wholly owned subsidiary valeant pharmaceutical international inc british columbia corporation “valeant” acquire outstanding share common stock par value 0001 per share company 15800 per share net seller cash without interest le required withholding tax upon term subject condition set forth offer purchase dated march 4 2015 a amended supplemented time time “offer purchase” related letter transmittal which together offer purchase may amended supplemented time time “offer” offer described tender offer statement schedule a amended supplemented time time filed sec valeant vpi purchaser march 4 2015 except otherwise set forth below information set forth schedule 14d9 remains unchanged incorporated reference relevant item amendment capitalized term used defined herein shall meaning assigned term schedule 14d9 amendment filed reflect certain update set forth below item 4 solicitation recommendation item 4 “the solicitation recommendation” schedule 14d9 hereby amended supplemented follows following paragraph hereby added immediately last paragraph heading “the solicitation recommendation — background offer merger” page 23 schedule 14d9 “on march 11 2015 company received unsolicited written proposal endo international plc “endo” acquire outstanding share combination 14607 share endo common stock 4500 cash per share the “proposal” march 11 2015 company provided copy proposal vpi accordance term merger agreement” item 9 exhibit item 9 schedule 14d9 hereby amended supplemented adding following exhibit exhibit description document a19 press release issued company dated march 11 2015 confirming receipt proposal 2 signature due inquiry best knowledge belief certify information set forth schedule 14d9 true complete correct salix pharmaceutical ltd dated march 12 2015 by s william bertrand jr name william c bertrand jr title acting chief operating officer executive vice president general counsel ex99a17 2 d884196dex99a17htm ex99a19 ex99a19 exhibit a19 contact g michael freeman stephen cohen associate vice president investor teneo strategy relation corporate communication 9198621000 3474896602 immediate release salix pharmaceutical ltd confirms receipt unsolicited proposal endo international plc raleigh nc – march 11 2015 – salix pharmaceutical ltd nasdaq slxp “salix” “company” today confirmed received unsolicited proposal endo international plc “endo” acquire outstanding share common stock company combination 14607 share endo common stock 4500 cash per share common stock company the “proposal” salix board director consultation financial legal advisor carefully review consider proposal pursue course action belief best interest company’s stockholder company’s stockholder need take action time previously announced salix party agreement plan merger dated february 20 2015 valeant pharmaceutical international inc certain subsidiary pursuant salix stockholder would receive amount cash equal 15800 per share share salix common stock own centerview partner llc jp morgan security llc serving financial advisor company cadwalader wickersham taft llp serving legal counsel company salix salix pharmaceutical ltd headquartered raleigh north carolina develops market prescription pharmaceutical product medical device prevention treatment gastrointestinal disease salix’s strategy inlicense latestage marketed proprietary therapeutic product complete required development regulatory submission product commercialize company’s 500member specialty sale force salix trade nasdaq global select market ticker symbol “slxp” forwardlooking statement press release may contain forwardlooking statement including limited to statement regarding proposed acquisition salix forwardlooking statement may generally identified use word “anticipates” “expects” “intends” “plans” “should” “could” “would” “may” “will” “believes” “estimates” “potential” “target” “continue” variation similar expression risk uncertainty include limited to risk uncertainty discussed salix’s recent annual quarterly report detailed time time salix’s filing security exchange commission the “sec” factor incorporated herein reference reader cautioned place undue reliance forwardlooking statement forwardlooking statement speak date hereof salix undertakes obligation update forwardlooking statement reflect event circumstance date press release reflect actual outcome important information investor security holder communication constitute offer buy solicitation offer sell security tender offer statement schedule to including offer purchase letter transmittal related document filed sec subsidiary valeant pharmaceutical international solicitationrecommendation statement schedule 14d9 filed sec salix tender offer made pursuant offer purchase letter transmittal related document filed part schedule to investor stockholder salix urged read tender offer statement solicitationrecommendation statement regarding tender offer amendment supplement thereto document filed sec become available contain or contain important information material sent free charge salix stockholder may also obtained salix’s website wwwsalixcom addition material and tender offer document filed sec available charge sec website wwwsecgov 2